Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

DUBbing Down Translation: The Functional Interaction of Deubiquitinases with the Translational Machinery.

Kapadia BB, Gartenhaus RB.

Mol Cancer Ther. 2019 Sep;18(9):1475-1483. doi: 10.1158/1535-7163.MCT-19-0307. Review.

PMID:
31481479
2.

Author Correction: Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 May 3;8(1):7221. doi: 10.1038/s41598-018-25251-9.

3.

Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.

Kapadia B, Nanaji NM, Bhalla K, Bhandary B, Lapidus R, Beheshti A, Evens AM, Gartenhaus RB.

Nat Commun. 2018 Feb 26;9(1):829. doi: 10.1038/s41467-018-03028-y.

4.

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 Jan 15;8(1):744. doi: 10.1038/s41598-018-19182-8. Erratum in: Sci Rep. 2018 May 3;8(1):7221.

5.

A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma.

Beheshti A, Vanderburg C, McDonald JT, Ramkumar C, Kadungure T, Zhang H, Gartenhaus RB, Evens AM.

PLoS One. 2017 Jan 20;12(1):e0170521. doi: 10.1371/journal.pone.0170521. eCollection 2017.

6.

Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.

Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM.

Cancer Res. 2016 Jun 1;76(11):3319-31. doi: 10.1158/0008-5472.CAN-15-2477. Epub 2016 Mar 17.

7.

Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders.

Dai B, Chen AY, Corkum CP, Peroutka RJ, Landon A, Houng S, Muniandy PA, Zhang Y, Lehrmann E, Mazan-Mamczarz K, Steinhardt J, Shlyak M, Chen QC, Becker KG, Livak F, Michalak TI, Talwani R, Gartenhaus RB.

Oncogene. 2016 Jun 9;35(23):2979-90. doi: 10.1038/onc.2015.364. Epub 2015 Oct 5.

8.

Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.

Gao Y, Gartenhaus RB, Lapidus RG, Hussain A, Zhang Y, Wang X, Dan HC.

Mol Cancer Res. 2015 Dec;13(12):1602-14. doi: 10.1158/1541-7786.MCR-15-0213. Epub 2015 Sep 15.

9.

Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.

Heredia A, Le N, Gartenhaus RB, Sausville E, Medina-Moreno S, Zapata JC, Davis C, Gallo RC, Redfield RR.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9412-7. doi: 10.1073/pnas.1511144112. Epub 2015 Jul 13.

10.

Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.

Mazan-Mamczarz K, Peroutka RJ, Steinhardt JJ, Gidoni M, Zhang Y, Lehrmann E, Landon AL, Dai B, Houng S, Muniandy PA, Efroni S, Becker KG, Gartenhaus RB.

Cell Commun Signal. 2015 Mar 1;13:15. doi: 10.1186/s12964-015-0091-0.

11.

MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.

Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden KL, Gartenhaus RB.

Nat Commun. 2014 Nov 18;5:5413. doi: 10.1038/ncomms6413.

12.

Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.

Steinhardt JJ, Peroutka RJ, Mazan-Mamczarz K, Chen Q, Houng S, Robles C, Barth RN, DuBose J, Bruns B, Tesoriero R, Stein D, Fang R, Hanna N, Pasley J, Rodriguez C, Kligman MD, Bradley M, Rabin J, Shackelford S, Dai B, Landon AL, Scalea T, Livak F, Gartenhaus RB.

Blood. 2014 Dec 11;124(25):3758-67. doi: 10.1182/blood-2014-07-589689. Epub 2014 Oct 15.

13.

The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.

Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, Evens AM.

Clin Cancer Res. 2014 Dec 1;20(23):6023-33. doi: 10.1158/1078-0432.CCR-14-1532. Epub 2014 Oct 14.

14.

Vγ2Vδ2 T cell Costimulation Increases NK cell Killing of Monocyte-derived Dendritic Cells.

Cairo C, Surendran N, Harris KM, Mazan-Mamczarz K, Sakoda Y, Diaz-Mendez F, Tamada K, Gartenhaus RB, Mann DL, Pauza CD.

Immunology. 2014 Sep 16. doi: 10.1111/imm.12386. [Epub ahead of print]

15.

Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development.

Mazan-Mamczarz K, Zhao XF, Dai B, Steinhardt JJ, Peroutka RJ, Berk KL, Landon AL, Sadowska M, Zhang Y, Lehrmann E, Becker KG, Shaknovich R, Liu Z, Gartenhaus RB.

PLoS Genet. 2014 Jan 30;10(1):e1004105. doi: 10.1371/journal.pgen.1004105. eCollection 2014 Jan.

16.

Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.

Chou FP, Chen YW, Zhao XF, Xu-Monette ZY, Young KH, Gartenhaus RB, Wang JK, Kataoka H, Zuo AH, Barndt RJ, Johnson M, Lin CY.

Am J Pathol. 2013 Oct;183(4):1306-17. doi: 10.1016/j.ajpath.2013.06.024.

17.

Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL).

Mazan-Mamczarz K, Gartenhaus RB.

Leuk Res. 2013 Nov;37(11):1420-8. doi: 10.1016/j.leukres.2013.08.020. Epub 2013 Sep 7. Review.

18.

Epigenetic approaches for chemosensitization of refractory diffuse large B-cell lymphomas.

Steinhardt JJ, Gartenhaus RB.

Cancer Discov. 2013 Sep;3(9):968-70. doi: 10.1158/2159-8290.CD-13-0358.

19.

c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas.

Hu F, Gartenhaus RB, Zhao XF, Fang HB, Minkove S, Poss DE, Rapoport AP.

Leuk Res. 2013 Apr;37(4):447-54. doi: 10.1016/j.leukres.2012.11.010. Epub 2012 Dec 10.

PMID:
23237560
20.

The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.

Wang D, Li L, Yang H, Ferguson SS, Baer MR, Gartenhaus RB, Wang H.

Blood. 2013 Jan 10;121(2):329-38. doi: 10.1182/blood-2012-06-436691. Epub 2012 Nov 16.

21.

Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.

Steinhardt JJ, Gartenhaus RB.

Clin Cancer Res. 2012 Sep 1;18(17):4538-48. doi: 10.1158/1078-0432.CCR-12-0217. Epub 2012 Jun 27. Review.

22.

Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma.

Dai B, Zhao XF, Mazan-Mamczarz K, Hagner P, Corl S, Bahassi el M, Lu S, Stambrook PJ, Shapiro P, Gartenhaus RB.

Nat Commun. 2011 Jul 19;2:402. doi: 10.1038/ncomms1404.

23.

Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for cancer immunotherapy.

Zhang Y, Pfannenstiel LW, Bolesta E, Montes CL, Zhang X, Chapoval AI, Gartenhaus RB, Strome SE, Gastman BR.

Clin Cancer Res. 2011 Aug 1;17(15):4975-86. doi: 10.1158/1078-0432.CCR-10-3328. Epub 2011 Jun 28.

24.

The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Bhalla S, Evens AM, Dai B, Prachand S, Gordon LI, Gartenhaus RB.

Blood. 2011 Jul 28;118(4):1052-61. doi: 10.1182/blood-2011-03-340109. Epub 2011 May 31.

25.

ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes.

Mazan-Mamczarz K, Hagner PR, Zhang Y, Dai B, Lehrmann E, Becker KG, Keene JD, Gorospe M, Liu Z, Gartenhaus RB.

Blood. 2011 Feb 24;117(8):2441-50. doi: 10.1182/blood-2010-09-310987. Epub 2011 Jan 5.

26.

Kernel based methods for accelerated failure time model with ultra-high dimensional data.

Liu Z, Chen D, Tan M, Jiang F, Gartenhaus RB.

BMC Bioinformatics. 2010 Dec 21;11:606. doi: 10.1186/1471-2105-11-606.

27.

Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5' terminal oligopyrimidine tract.

Hagner PR, Mazan-Mamczarz K, Dai B, Balzer EM, Corl S, Martin SS, Zhao XF, Gartenhaus RB.

Oncogene. 2011 Mar 31;30(13):1531-41. doi: 10.1038/onc.2010.533. Epub 2010 Nov 22.

28.

AMPK signaling: a targetable tumor suppressor pathway?

Schneider A, Gartenhaus RB.

Cancer Biol Ther. 2010 Dec 1;10(11):1178-81. Epub 2010 Dec 1. No abstract available.

29.

PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.

Hu F, Gartenhaus RB, Eichberg D, Liu Z, Fang HB, Rapoport AP.

Oncogene. 2010 Oct 7;29(40):5464-74. doi: 10.1038/onc.2010.275. Epub 2010 Jul 12.

PMID:
20622899
30.

Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer.

Zhou H, Mazan-Mamczarz K, Martindale JL, Barker A, Liu Z, Gorospe M, Leedman PJ, Gartenhaus RB, Hamburger AW, Zhang Y.

Nucleic Acids Res. 2010 Jun;38(11):3619-31. doi: 10.1093/nar/gkq084. Epub 2010 Feb 16.

31.

Targeting the translational machinery as a novel treatment strategy for hematologic malignancies.

Hagner PR, Schneider A, Gartenhaus RB.

Blood. 2010 Mar 18;115(11):2127-35. doi: 10.1182/blood-2009-09-220020. Epub 2010 Jan 14. Review.

32.

Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.

Dai B, Zhao XF, Hagner P, Shapiro P, Mazan-Mamczarz K, Zhao S, Natkunam Y, Gartenhaus RB.

Cancer Res. 2009 Oct 1;69(19):7835-43. doi: 10.1158/0008-5472.CAN-09-1606. Epub 2009 Sep 29.

33.

Survival prediction and gene identification with penalized global AUC maximization.

Liu Z, Gartenhaus RB, Chen XW, Howell CD, Tan M.

J Comput Biol. 2009 Dec;16(12):1661-70. doi: 10.1089/cmb.2008.0188.

34.

Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma.

Zhao XF, Gartenhaus RB.

Expert Opin Ther Targets. 2009 Sep;13(9):1085-93. doi: 10.1517/14728220903103833. Review.

PMID:
19614561
35.

Alcohol consumption and decreased risk of non-Hodgkin lymphoma: role of mTOR dysfunction.

Hagner PR, Mazan-Mamczarz K, Dai B, Corl S, Zhao XF, Gartenhaus RB.

Blood. 2009 May 28;113(22):5526-35. doi: 10.1182/blood-2008-11-191783. Epub 2009 Mar 17.

36.

Gene and pathway identification with Lp penalized Bayesian logistic regression.

Liu Z, Gartenhaus RB, Tan M, Jiang F, Jiao X.

BMC Bioinformatics. 2008 Oct 3;9:412. doi: 10.1186/1471-2105-9-412.

37.

Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach.

Mazan-Mamczarz K, Hagner PR, Dai B, Wood WH, Zhang Y, Becker KG, Liu Z, Gartenhaus RB.

Cancer Res. 2008 Oct 1;68(19):7730-5. doi: 10.1158/0008-5472.CAN-08-2393.

38.

Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism.

Mazan-Mamczarz K, Hagner P, Dai B, Corl S, Liu Z, Gartenhaus RB.

Leuk Res. 2009 Mar;33(3):474-82. doi: 10.1016/j.leukres.2008.08.012. Epub 2008 Sep 27.

PMID:
18824261
39.

Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.

Mazan-Mamczarz K, Hagner PR, Corl S, Srikantan S, Wood WH, Becker KG, Gorospe M, Keene JD, Levenson AS, Gartenhaus RB.

Oncogene. 2008 Oct 16;27(47):6151-63. doi: 10.1038/onc.2008.215. Epub 2008 Jul 21.

40.

Post-transcriptional control of the MCT-1-associated protein DENR/DRP by RNA-binding protein AUF1.

Mazan-Mamczarz K, Gartenhaus RB.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):233-9.

41.

The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation.

Vitolo MI, Anglin IE, Mahoney WM Jr, Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A.

Cancer Biol Ther. 2007 Jun;6(6):856-63. Epub 2007 Mar 1.

PMID:
17438369
42.

MCT-1 oncogene downregulates p53 and destabilizes genome structure in the response to DNA double-strand damage.

Hsu HL, Choy CO, Kasiappan R, Shih HJ, Sawyer JR, Shu CL, Chu KL, Chen YR, Hsu HF, Gartenhaus RB.

DNA Repair (Amst). 2007 Sep 1;6(9):1319-32. Epub 2007 Apr 6.

PMID:
17416211
43.

Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism.

Phatak P, Cookson JC, Dai F, Smith V, Gartenhaus RB, Stevens MF, Burger AM.

Br J Cancer. 2007 Apr 23;96(8):1223-33. Epub 2007 Apr 3.

44.

Expression of DNA mismatch repair proteins in transformed non-Hodgkin's lymphoma: relationship to smoking.

Nandi S, Yu J, Burger AM, Reinert LS, Gartenhaus RB.

Leuk Lymphoma. 2006 Sep;47(9):1806-12.

PMID:
17064992
45.

Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage.

Nandi S, Reinert LS, Hachem A, Mazan-Mamczarz K, Hagner P, He H, Gartenhaus RB.

Oncogene. 2007 Apr 5;26(16):2283-9. Epub 2006 Oct 2.

PMID:
17016429
46.

MCT-1 protein interacts with the cap complex and modulates messenger RNA translational profiles.

Reinert LS, Shi B, Nandi S, Mazan-Mamczarz K, Vitolo M, Bachman KE, He H, Gartenhaus RB.

Cancer Res. 2006 Sep 15;66(18):8994-9001.

47.

Characterization of the MCT-1 pseudogene: identification and implication of its location in a highly amplified region of chromosome 20.

Nandi S, Shi B, Perreault J, Gartenhaus RB.

Biochim Biophys Acta. 2006 May;1759(5):234-9. Epub 2006 May 22.

PMID:
16815567
48.

MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.

Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL Jr, Gartenhaus RB.

Cancer Res. 2005 Dec 1;65(23):10651-6.

49.

MSRE-PCR for analysis of gene-specific DNA methylation.

Melnikov AA, Gartenhaus RB, Levenson AS, Motchoulskaia NA, Levenson Chernokhvostov VV.

Nucleic Acids Res. 2005 Jun 8;33(10):e93.

50.

Supplemental Content

Loading ...
Support Center